Authors
Latest:
Successful Social Communications The What Vs The HowGo to any communications seminar, forum, convention or workshop right now and the program will be populated with the latest and greatest trends in social communication platforms and how important these are if you want to be successful
Latest:
Assessing the Value of Retrospective Studies Real World Data Real World ApplicationsThe value of retrospective studies cannot be overstated. Retrospective studies affect many healthcare sectors, including the pharmaceutical industry and general public health
Latest:
Orphan Drug Laws A Pharmacists PerspectivePharm Exec’s sister organization CBI hosted its annual Orphan Drug Innovation Summit in Philadelphia on July 17-18. This is a topic that I have professional interest in, as well as a general curiosity.
Latest:
Challenges to the Specialty Business ModelBiopharmaceutical drug discovery companies have progressively tailored their pipelines to specialty therapeutic areas and smaller patient populations.
Latest:
Challenges to the Specialty Business ModelBiopharmaceutical drug discovery companies have progressively tailored their pipelines to specialty therapeutic areas and smaller patient populations.
Latest:
Challenges to the Specialty Business ModelBiopharmaceutical drug discovery companies have progressively tailored their pipelines to specialty therapeutic areas and smaller patient populations.
Latest:
Messaging in Healthcare: Making Sound and Fury Signify SomethingRecently, there was a bit of a dust-up over whether it was appropriate for the Secretary of Health and Human Services (HHS) to engage the National Football League (NFL) to help HHS with the process of drumming-up enrollment for health insurance exchanges. In the end, the NFL and other sports leagues decided they were not going to be involved fearing the appearance of taking political sides.
Latest:
Medicare “Wasting Billions of Dollars”, Says StudyPoorer people are being prescribed more expensive branded drugs. Is that bad? According to a new investigation it is. And it is costing the taxpayers a shovel-load of money. Furthermore, it’s unnecessary.
Latest:
Despite Growing Momentum, Repeal of Medical Device Tax Faces Significant HurdlesOn March 21, 2013, the United States Senate approved an amendment by a vote of 79 to 20 to repeal the 2.3 percent medical device excise tax.
Latest:
Value-Based Healthcare in the UKJill E. Sackman and Michael Kuchenreuther look at some of the pricing and reimbursement challenges in the UK and offer strategies manufacturers should consider for sustainable success.
Latest:
Marketing: Harnessing the Power of 'Pull'Since the early days of the internet, we’ve been busy creating websites and other digital channels.
Latest:
Is the Hatch-Waxman System Broken?While the 1984 Act has been a boon for lower-cost generics, its goal of incentivizing new drug discovery has failed.
Latest:
Is the Hatch-Waxman System Broken?While the 1984 Act has been a boon for lower-cost generics, its goal of incentivizing new drug discovery has failed.
Latest:
Remote Patient Monitoring: 2014 OutlookHistorically, pharmaceutical companies have leveraged remote patient monitoring (RPM) in a very limited way to improve data collection in clinical trials.
Latest:
Ladders Down! Successful Women Need to Help Others Come Up the Rank.“Leaning in” might be all the rage – but “hanging in” is just as important to make sure women gather momentum in the workplace. At a meeting of the Global Women in Business Advisory Council last week in Palm Springs, CA, members discussed ways to build critical mass for stronger female participation in the workplace.
Latest:
The Amazon Effect: A Data-Fueled Customer ExperienceWhat the future emergence of Amazon Pharmacy and the company’s aim to own the health experience may mean for pharma manufacturers’ engagement strategies and role in Rx delivery.
Latest:
Single Payer Issue Will Rise AgainThe future of healthcare centers on scale, population health and the value of care rather than the volume of care, according to thought leaders speaking at a leadership briefing in November in Akron, Ohio. But the political atmosphere also adds layers of complexity, they say.
Latest:
EMRs and Registries in the Era of Healthcare ReformAdvances in health information technology and new federal financial incentives are fueling rapid growth in the use of electronic medical record (EMR) systems
Latest:
Winning Pharma's Super ConferencesLike the Super Bowl, pharma companies are winning major congresses by using competitive conference techniques to generate brand buzz and corporate recognition.
Latest:
Beyond the Science: Commercial Implications From ASCO 2017Four strategic takeaways from this year's that are important for pharma oncology leaders.
Latest:
Biotech Performance Pivot May Be in the OffingWith a likely rate cut by the Federal Reserve this week, investors could rotate aggressively back to the sector.
Latest:
The Myriad Ruling: Six Points Every Biotech CEO Must ConsiderLast week, the US Supreme Court issued a long-awaited decision in Myriad Genetics, which sent shockwaves through the very foundation of the biotech industry
Latest:
Accept It, Wikipedia Is a Public Health Issue. Now Let's Fix It.Medical articles on Wikipedia receive about 150 million page views per month, and nearly 50% of practicing physicians use Wikipedia as an information source for providing medical care. And while Wikipedia itself has disclaimers that information included on its site may be inaccurate,
Latest:
Marketing is Pre-SalesNot long ago, I was privy to a discussion taking place in a large drug development services company.
Latest:
Five Ways Advanced Social Intelligence Guides Pharma StrategyWithin the billions of daily comments from individuals across open social sources lies deep intelligence into markets, brands, patients, caregivers, healthcare providers and competitors.
Latest:
Drug Patents Under Fire in BrazilOne of the most promising pharmaceutical markets of the future is Brazil, a nation of nearly 200 million people with a universal healthcare system.
Latest:
Drug Patents Under Fire in BrazilOne of the most promising pharmaceutical markets of the future is Brazil, a nation of nearly 200 million people with a universal healthcare system.
Latest:
Protecting Your Online ReputationFor CEOs who have spent long years and countless funds building a solid pharmaceutical brand and life-changing drugs, discovering defamatory remarks about your company online can come as quite a shock.
Latest:
Dissecting ACA's Section 6004: Tipping the Balance on Sampling Controls?With the Affordable Care Act [ACA] officially settling into the US’ political landscape, a pressing – but little noticed – issue is the provisions for increased compliance on industry promotion practices.
Latest:
Three Questions to Ask About Your Life Sciences PatentsThe decisions you make today about patents – what, when and where to file – could have implications tantamount to billions of dollars in R&D investment and sales over the next two decades.
